In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Akari Therapeutics (AKTX – Research Report), with a price target of $5.00. The company’s shares closed last Monday at $2.15.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 14.2% and a 46.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akari Therapeutics with a $5.00 average price target.
Based on Akari Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.88 million. In comparison, last year the company had a GAAP net loss of $3.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.